Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2024-12-15 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物关于修订上市前制定的股权激励计划的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the board of directors of Maiwei (Shanghai) Biotechnology Co., Ltd. regarding revisions to a pre-IPO equity incentive plan. It details specific changes to the rules governing the transfer of shares under the equity incentive plan and states that the revisions will be submitted to the shareholders' meeting for approval. The document is a formal announcement about changes in a stock incentive plan, which relates to capital structure and financing activities. It is not a full report, financial statement, or regulatory certification. Given the content and context, this fits best under Capital/Financing Update (CAP). The document length is short and focused on the equity incentive plan revision, not a full report or meeting materials, so it is not AGM-R or PSI. Therefore, the classification is CAP with high confidence.
2024-12-15 Chinese
迈威生物第二届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of a company regarding the approval and planning for an overseas public offering of H shares and listing on the Hong Kong Stock Exchange. It includes detailed proposals on the issuance plan, pricing, underwriting, governance changes, appointment of directors and officers, and various governance policies to be adopted post-listing. The document is lengthy (15,000 characters) and contains substantive content about board decisions and management changes, including nominations and appointments of directors and senior management. It is not a financial report, earnings release, or regulatory filing of financial results. It is not a proxy solicitation or voting results announcement, but rather a formal board meeting resolution announcement. Therefore, the best fitting category is Board/Management Information (MANG), as it primarily concerns board decisions and management appointments related to the company's capital raising and listing plans.
2024-12-15 Chinese
迈威生物第二届监事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 14th meeting of the second Supervisory Board of Maiwei (Shanghai) Biotech Co., Ltd. The content includes approval of proposals related to the company's plan to publicly issue H shares overseas and list on the Hong Kong Stock Exchange main board, including issuance details, pricing, underwriting, use of proceeds, and governance changes. The document is a formal meeting resolution announcement by the Supervisory Board, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or earnings data but focuses on governance and corporate actions requiring shareholder approval. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management bodies. The document is substantive and over 5,000 characters, so it is not a mere announcement of a report publication (RPA) or a regulatory filing (RNS). Therefore, the best classification is MANG with high confidence.
2024-12-15 Chinese
《迈威（上海）生物科技股份有限公司董事会议事规则》（草案）
Governance Information Classification · 100% confidence The document is titled "董事会议事规则" which translates to "Board Meeting Rules" or "Rules of Procedure for the Board of Directors". It details the composition, responsibilities, meeting procedures, voting rules, and committees of the company's board of directors. It references relevant laws and listing rules, including the Hong Kong Stock Exchange listing rules and Shanghai Stock Exchange rules. The content is focused on governance structure and internal board management practices rather than financial results, audit opinions, or shareholder meeting materials. It is not a report of financial performance, audit, or earnings, nor is it an announcement or transcript. It is a governance document outlining the internal rules and procedures of the board. Therefore, the appropriate classification is Governance Information (CGR). The document length and detail support this classification with high confidence.
2024-12-15 Chinese
海通证券股份有限公司关于迈威（上海）生物科技股份有限公司预计2025年度日常关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a sponsoring securities company (Haitong Securities) regarding the anticipated related party transactions for the fiscal year 2025 of Maiwei (Shanghai) Biotechnology Co., Ltd. It includes descriptions of the review and approval procedures by the board, audit committee, supervisory board, and independent directors, as well as detailed financial estimates and explanations of the related party transactions. The document is not a brief announcement but a substantive report containing financial data and governance details about related party transactions. It is not an annual or interim financial report, nor is it a regulatory filing or announcement. The content aligns with a specialized audit or review report on related party transactions, which fits best under the category of Audit Report / Information (AR). The document length (5673 characters) supports it being a full report rather than a brief announcement. Therefore, the classification is AR with high confidence.
2024-12-15 Chinese
迈威生物独立董事候选人声明与承诺（王芳）
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate for a company's board, detailing qualifications, independence criteria, and compliance with regulatory requirements. It is not a financial report, earnings release, or any form of meeting material. It does not announce voting results or changes in management but is related to board/management information specifically about a director candidate's qualifications and commitments. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on a single candidate's statement, confirming it is not a full report or announcement of a report.
2024-12-15 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.